CA2226255A1 - Chromosome 1 gene and gene products related to alzheimer's disease - Google Patents

Chromosome 1 gene and gene products related to alzheimer's disease Download PDF

Info

Publication number
CA2226255A1
CA2226255A1 CA002226255A CA2226255A CA2226255A1 CA 2226255 A1 CA2226255 A1 CA 2226255A1 CA 002226255 A CA002226255 A CA 002226255A CA 2226255 A CA2226255 A CA 2226255A CA 2226255 A1 CA2226255 A1 CA 2226255A1
Authority
CA
Canada
Prior art keywords
nucleic acid
gene
protein
disease
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002226255A
Other languages
English (en)
French (fr)
Inventor
Rudolph E. Tanzi
Gerard D. Schellenberg
Wilma Wasco
Thomas D. Bird
John Mulligan
David J. Galas
Ephrat Levy-Lahad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
UCB Manufacturing Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2226255A1 publication Critical patent/CA2226255A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002226255A 1995-07-07 1996-07-05 Chromosome 1 gene and gene products related to alzheimer's disease Abandoned CA2226255A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US95695P 1995-07-07 1995-07-07
US167595P 1995-07-28 1995-07-28
US217495P 1995-08-11 1995-08-11
US232895P 1995-08-14 1995-08-14
US60/000,956 1995-08-14
US60/002,328 1995-08-14
US60/001,675 1995-08-14
US60/002,174 1995-08-14

Publications (1)

Publication Number Publication Date
CA2226255A1 true CA2226255A1 (en) 1997-01-30

Family

ID=27485043

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002226255A Abandoned CA2226255A1 (en) 1995-07-07 1996-07-05 Chromosome 1 gene and gene products related to alzheimer's disease

Country Status (7)

Country Link
US (2) US6468791B1 (https=)
EP (2) EP1637600A1 (https=)
JP (3) JP4073955B2 (https=)
AT (1) ATE305039T1 (https=)
CA (1) CA2226255A1 (https=)
DE (1) DE69635207T2 (https=)
WO (1) WO1997003192A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531586B1 (en) 1995-04-28 2003-03-11 The Hospital For Sick Children Genetic sequences related to Alzheimer's Disease
JP5379119B2 (ja) * 1995-04-28 2013-12-25 エイチエスシー リサーチ アンド ディベロップメント リミテッド アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6210919B1 (en) 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
EP0846172A2 (en) * 1995-08-16 1998-06-10 The President And Fellows Of Harvard College Assay for identifying genes causing chromosome non-disjunction
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
ES2128265B1 (es) * 1997-06-04 2000-03-01 Euroespes S A Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
AU1957299A (en) 1998-01-09 1999-07-26 Governing Council Of The University Of Toronto, The Presenilin protein interactions
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
JP2003018991A (ja) * 2001-06-27 2003-01-21 Japan Science & Technology Corp プレセニリン−２遺伝子エキソン５欠損型スプライシング異常の生成に関与する核酸
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP5124569B2 (ja) * 2006-06-12 2013-01-23 カー−バー インヴェストメンツ インコーポレイテッド ノズル検査装置および方法
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
BR112014013942B1 (pt) * 2011-12-20 2021-03-02 Unilever Ip Holdings B.V composição detergente líquida isotrópica
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210919B1 (en) * 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease

Also Published As

Publication number Publication date
EP0846171A2 (en) 1998-06-10
JP4073955B2 (ja) 2008-04-09
US6468791B1 (en) 2002-10-22
US20030180880A1 (en) 2003-09-25
JP2008035862A (ja) 2008-02-21
WO1997003192A2 (en) 1997-01-30
WO1997003192A3 (en) 1997-04-03
DE69635207D1 (de) 2006-02-02
JP2001517922A (ja) 2001-10-09
EP1637600A1 (en) 2006-03-22
EP0846171B1 (en) 2005-09-21
ATE305039T1 (de) 2005-10-15
JP2008035863A (ja) 2008-02-21
DE69635207T2 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
CA2226255A1 (en) Chromosome 1 gene and gene products related to alzheimer's disease
WO1997003192A9 (en) Chromosome 1 gene and gene products related to alzheimer's disease
US20080131411A1 (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
EP0953043B1 (en) Genes and gene products related to werner's syndrome
WO1997024435A9 (en) Genes and gene products related to werner's syndrome
US6248555B1 (en) Genetic alterations related to familial alzheimer's disease
MXPA98001603A (en) Genetic alterations related to the disease of alzheimer heredita

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140707